A Reasonably Likely Surrogate Endpoint For Metabolic Dysfunction–Associated Steatohepatitis

28 Apr 20264 min read0 viewsJournal Feed

GIST

Chronic liver disease is a leading cause of mortality worldwide. Metabolic dysfunction–associated steatotic liver disease and its histologically active form, metabolic dysfunction–associated steatohepatitis (MASH), are highly prevalent and progress to cirrhosis and related complications.

such as ascites, encephalopathy or variceal hemorrhage. over years to decades.

Much of the current knowledge that has driven both clinical practice and approaches to drug development is based on histological assessment of the presence of steatohepatitis and fibrosis stage of disease 1 . Specifically, the current regulatory path for accelerated drug approval for non-cirrhotic stages of MASH requires demonstration of resolution of steatohepatitis without worsening of fibrosis and/or improvement in fibrosis stage without worsened steatohepatitis.

These are considered to be reasonably likely surrogate endpoints (RLSEs) and allow drug approval that is conditional on the demonstration that these translate to reduced progression to cirrhosis and improved clinical outcomes 2 . The status quo has many limitations.

It requires liver biopsy, which is invasive and associated with the potential for severe morbidity and even death, and is further negatively impacted by sampling and observer variability 3 .

Clinical Editorial

Context and objective integrity

The communication centers on metabolic dysfunction–associated steatohepatitis (MASH) and its significance as a progressive liver disease linked to cirrhosis-related complications.
The article discusses the current regulatory pathway for accelerated drug approval in non-cirrhotic MASH, which hinges on surrogate endpoints that are reasonably likely to predict clinical benefit: resolution of steatohepatitis without fibrosis worsening, or improvement in fibrosis without worsening steatohepatitis.
The overarching aim is to move beyond histology-based assessment toward non-invasive tools (NITs) to support drug development and routine clinical practice, addressing barriers such as the invasiveness of liver biopsy, sampling and observer variability, and limited applicability to real-world care.

Study design and scenaio (as presented in the source)

The piece is a research highlights overview that reflects consensus-building activities and plans organized by the FNIH (Foundation for the National Institutes of Health) and the MASHtrack surrogate endpoints working group, in collaboration with the Nonalcoholic Steatohepatitis Clinical Research Network ancillary study.
It emphasizes that although substantial literature exists on non-invasive test (NIT) approaches for metabolic dysfunction–associated steatotic liver disease, many data do not meet regulatory standards, and gaps remain that impede qualification of RLSEs.

Population and intervention exposure (described, not quantified)

The target population includes individuals with metabolic dysfunction–associated steatotic liver disease, particularly those at risk for progression to metabolic dysfunction–associated steatohepatitis and cirrhosis.
The text references non-invasive tools and strategies intended to replace or supplement histological endpoints in both research and routine clinical practice, with an emphasis on feasibility, access, and trial recruitment benefits.

Key concepts and findings (evidence landscape and rationale)

Current reliance on histology for regulatory endpoints imposes substantial burdens: the need for liver biopsy, associated risk, and sampling/observer variability, contributing to high screen failure rates in trials.
Histology-based endpoints are rarely used in everyday clinical practice, hindering translation of trial results into guideline-based care and timely identification of at-risk patients.
There is a recognized need for non-invasive endpoints that can be broadly deployed across clinical settings to improve access to care, trial recruitment, and the speed at which effective therapies reach patients.
While numerous NIT studies exist, the regulatory pathway requires endpoints that meet stringent standards for surrogate validity, which most existing data have not yet satisfied.

Limitations and uncertainties

The describe-and-justify narrative acknowledges data gaps that prevent current NITs from being qualified as RLSEs suitable for regulatory approval in MASH.
It explicitly notes that the FNIH did not direct the scientific content; instead, the material reflects multi-stakeholder planning and consensus processes.

Operational implications and future directions

The emphasis is on developing and validating non-invasive endpoints that align with regulatory expectations while enabling practical deployment in diverse clinical environments.
The aim is to establish RLSEs that can predict progression to cirrhosis and related outcomes, thereby facilitating earlier intervention and improved patient access to care.
The initiative highlights the need for robust, regulatory-grade evidence to support non-invasive endpoints and to bridge trial data with real-world practice.

Open questions and limitations in reporting

It remains unclear from the summarized content whether specific NITs or candidate RLSEs have demonstrated validated performance to regulatory thresholds, or which particular measures are most promising.
The article does not provide numerical results, comparative analyses, or explicit performance metrics for any candidate endpoints.
The scope is focused on the strategic and methodological rationale rather than presenting new empirical findings; limitations in the source include the absence of concrete data points or validated endpoint exemplars.

Editorial perspective and practical relevance

This briefing underscores a pivotal shift from biopsy-centric paradigms toward accessible, non-invasive strategies to gauge disease activity and treatment impact in MASH.